The Injection Practice Patterns of Retina Specialists in Managing Exudative Age-Related Macular Degeneration: A Retrospective Study

References

• Gheorghe A, Mahdi L, Musat O. Age-related macular degeneration. Rom J Ophthalmol. 2015;59(2):74–77.
   PubMedGoogle Scholar
• Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147–1159. doi:10.1016/S0140-6736(18)31550-2
   PubMed Web of Science ®Google Scholar
• Seddon JM. Epidemiology of age-related macular degeneration. In: Schachat AP, Ryan S, editors. Retina. 3rd ed. St. Louis (MO): Mosby; 2001:1039–1050.
   Google Scholar
• Van Lookeren Campagne M, LeCouter J, Yaspan BL, Ye W. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 2014;232(2):151–164.
   PubMed Web of Science ®Google Scholar
• Coleman HR, Chan CC, Ferris FL, Chew EY. Age-related macular degeneration. Lancet. 2008;372(9652):1835–1845. doi:10.1016/S0140-6736(08)61759-6
   PubMed Web of Science ®Google Scholar
• Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728–1738. doi:10.1016/S0140-6736(12)60282-7
   PubMed Web of Science ®Google Scholar
• Bourne RRA, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Heal. 2013;1(6):339–349.
   PubMed Web of Science ®Google Scholar
• Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146–152. doi:10.1016/j.ophtha.2014.07.041
   PubMed Web of Science ®Google Scholar
• Gillies MC, Hunyor AP, Arnold JJ, et al. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2019;137(4):372–379.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Erie JC, Barkmeier AJ, Hodge DO, Mahr MA. High variation of intravitreal injection rates and medicare anti-vascular endothelial growth factor payments per injection in the United States. Ophthalmology. 2016;123(6):1257–1262. doi:10.1016/j.ophtha.2016.02.015
   PubMed Web of Science ®Google Scholar
• El-Mollayess GM, Mahfoud Z, Schakal AR, Salti HI, Jaafar D, Bashshur ZF. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study. Am J Ophthalmol. 2012;153(3):481–489.e1. doi:10.1016/j.ajo.2011.08.018
   PubMed Web of Science ®Google Scholar
• Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181–2192. doi:10.1016/j.ophtha.2014.05.009
   PubMed Web of Science ®Google Scholar
• Feltgen N, Bertelmann T, Bretag M, et al. Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial. Graefes Arch Clin Exp Ophthalmol. 2017;255(5):923–934. doi:10.1007/s00417-017-3589-x
   PubMed Web of Science ®Google Scholar
• Kertes PJ, Galic IJ, Greve M, et al. Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized Canadian treat-and-extend analysis trial with ranibizumab study. Ophthalmology. 2019;126(6):841–848. doi:10.1016/j.ophtha.2019.01.013
   PubMed Web of Science ®Google Scholar
• Eldem BM, Muftuoglu G, Topbaş S, et al. A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD. Acta Ophthalmol. 2015;93(6):e458–64. doi:10.1111/aos.12540
   PubMed Web of Science ®Google Scholar
• Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3(3):1.
   Google Scholar
• Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96(3):572–580. doi:10.1016/j.kint.2019.02.042
   PubMed Web of Science ®Google Scholar
• Porta M, Striglia E. Intravitreal anti-VEGF agents and cardiovascular risk. Intern Emerg Med. 2020;15(2):199–210. doi:10.1007/s11739-019-02253-7
   PubMed Web of Science ®Google Scholar
• Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C. Experiences of patients undergoing anti-VEGF treatment for neovascular age-related macular degeneration: a systematic review. Psychol Heal Med. 2015;20(3):296–310. doi:10.1080/13548506.2014.936886
   PubMed Web of Science ®Google Scholar
• Lee WJ, Cho HY, Kim DH, et al. Depression of late age-related macular degeneration patients in Korea. Asia Pacific J Ophthalmol. 2013;2(1):23–27. doi:10.1097/APO.0b013e31827be8b1
   PubMedGoogle Scholar
• Moisseiev E, Regenbogen M, Bartfeld Y, Barak A. Evaluation of pain in intravitreal bevacizumab injections. Curr Eye Res. 2012;37(9):813–817. doi:10.3109/02713683.2012.681335
   PubMed Web of Science ®Google Scholar
• Gurung RL, Fitzgerald LM, McComish BJ, Hewitt AW, Verma N, Burdon KP. Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice. BMJ Open Ophthalmol. 2021;6(1):1–9.
   Web of Science ®Google Scholar
• Ying G, Maguire MG, Pan W, et al. Baseline predictors for five-year visual acuity outcomes in the comparison of AMD treatment trials. Ophthalmol Retin. 2018;2(6):525–530. doi:10.1016/j.oret.2017.10.003
   PubMedGoogle Scholar
• Lotery A, Griner R, Ferreira A, Milnes F, Dugel P. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Eye. 2017;31(12):1697–1706. doi:10.1038/eye.2017.143
   PubMed Web of Science ®Google Scholar